Core Viewpoint - HeartTech Medical (02291) reported strong mid-term performance with a revenue of 330 million RMB, representing a year-on-year growth of 32.4%, and a net profit attributable to shareholders of 182 million RMB, up 29.8% [1] Company Performance - The company’s basic earnings per share reached 0.5249 RMB [1] - As of the announcement date, HeartTech Medical has a total of 30 products in the market, including occluders, heart valves, and accessories, with 4 products under registration review and 28 products in various stages of research and development [1] Product Pipeline and Market Position - According to CITIC Securities, HeartTech Medical has a comprehensive layout in the structural heart disease sector, covering products for congenital heart disease occluders, cardioembolic stroke, valves, and heart failure [1] - The company has a rich pipeline in the valve sector, with TAVR products already approved for market [1] - In the aortic and peripheral occluder fields, the company is developing biodegradable aortic occluders [1] Growth Drivers and Future Potential - The company has maintained rapid growth in recent years, primarily driven by the market expansion of new products such as biodegradable occluders [1] - HeartTech Medical's biodegradable occluder technology is at a leading level globally, with independent intellectual property rights [1] - There is potential for strong overseas license-out opportunities for this product series, considering the high costs of overseas clinical research and the company's technological advantages [1]

Core Viewpoint - HeartTech Medical (02291) reported strong mid-term performance with a revenue of 330 million RMB, reflecting a year-on-year growth of 32.4%, and a net profit attributable to shareholders of 182 million RMB, up 29.8% [1] Financial Performance - Revenue reached 330 million RMB, representing a 32.4% increase year-on-year [1] - Net profit attributable to shareholders was 182 million RMB, showing a growth of 29.8% [1] - Basic earnings per share stood at 0.5249 RMB [1] Product Portfolio - The company has a total of 30 marketed products including occluders, heart valves, and accessories [1] - There are 4 products under registration review and preparation, with an additional 28 products in various stages of research and development [1] Market Position and Growth Potential - CITIC Securities highlighted HeartTech Medical's comprehensive layout in the structural heart disease sector, covering areas such as congenital heart disease occluders, stroke, valves, and heart failure [1] - The company has a rich pipeline in the valve sector, with TAVR products already approved for market [1] - HeartTech Medical is positioned in the biodegradable aortic occluder market, which is expected to have strong overseas licensing potential due to its leading technology and proprietary intellectual property [1]

公告称，先天性心脏病封堵器产品的销售收入是集团收入的重要组成部分，由截至2024年6月30日止六 个月的1.29亿元增加24.9%至截至2025年6月30日止六个月的1.61亿元，分别占集团同期收入的51.6%及 48.7%。先天性心脏病封堵器产品的销售收入能够实现较快增长，主要由于集团的传统金属封堵器产品 收入稳健增长的同时，集团的第四代MemoSorb生物可降解室间隔封堵器和房间隔缺损封堵器顺利获证 并快速实现商业化后，带来了可观的增量收入，同时集团也正在通过可降解技术实现产品迭代和产品差 异化竞争格局。 心泰医疗(02291)发布截至2025年6月30日止六个月的中期业绩，营业总收入3.3亿元(人民币，下同)，同 比增加32.36%;归母净利润1.82亿元，同比增加29.81%;每股基本盈利0.5249元。 ...

Core Viewpoint - HeartTech Medical (02291) reported a significant increase in revenue and net profit for the six months ending June 30, 2025, indicating strong growth in its congenital heart disease occluder products and successful commercialization of new biodegradable devices [1] Financial Performance - Total revenue reached 330 million RMB, representing a year-on-year increase of 32.36% [1] - Net profit attributable to shareholders was 182 million RMB, up 29.81% year-on-year [1] - Basic earnings per share stood at 0.5249 RMB [1] Product Performance - Sales revenue from congenital heart disease occluders increased from 129 million RMB for the six months ending June 30, 2024, to 161 million RMB for the same period in 2025, accounting for 51.6% and 48.7% of total revenue, respectively [1] - The growth in sales revenue is attributed to steady growth in traditional metal occluder products and successful commercialization of the fourth-generation MemoSorb® biodegradable septal occluder and atrial septal defect occluder [1] - The company is focusing on product iteration and differentiation through biodegradable technology [1]

Core Viewpoint - The company reported a significant increase in revenue and net profit for the six months ending June 30, 2025, indicating strong growth in its operations within the cardiac medical device sector [1]. Financial Performance - Revenue increased by 32.4% year-on-year to RMB 330 million [1] - Net profit attributable to shareholders rose by 29.8% year-on-year to RMB 182 million [1] - Basic earnings per share were reported at RMB 0.5249 [1] - The board of directors did not recommend the payment of an interim dividend for the six months ending June 30, 2025 [1] Business Focus and Strategy - The company has over 20 years of experience in the development, production, and commercialization of cardiac medical intervention devices [1] - It is successfully implementing the biodegradability of medical devices and exploring advanced fields such as cardiac valves, mechanical circulatory support, and atrial septal puncture [1] - As a leader in China's interventional medical device industry, the company aims to provide safe, efficient, innovative, and comprehensive medical solutions [1] Product Portfolio - The company currently has 30 products in the market, including occluders, cardiac valves, and accessories [1] - There are 4 products undergoing registration review and preparation [1] - An additional 28 products are in various stages of research and development, including occluders, cardiac valves, surgical accessories, and mechanical circulatory support devices [1]

[Financial Highlights](index=1&type=section&id=%E8%B2%A1%E5%8B%99%E6%91%98%E8%A6%81) During the reporting period, the company achieved significant growth in revenue, gross profit, R&D expenses, and net profit attributable to parent company shareholders, but the board does not recommend an interim dividend Financial Highlights for the Six Months Ended June 30, 2025 | Indicator | June 30, 2025 (RMB million) | June 30, 2024 (RMB million) | Year-over-year growth rate (%) | | :--- | :--- | :--- | :--- | | Revenue | 329.7 | 249.1 | 32.4 | | Gross Profit | 284.3 | 226.7 | 25.4 | | R&D Expenses | 25.4 | 21.7 | 17.0 | | Net Profit Attributable to Parent Company Shareholders | 182.0 | 140.2 | 29.8 | - The Board does not recommend an interim dividend for the six months ended June 30, 2025 (for the six months ended June 30, 2024: nil)[5](index=5&type=chunk) [Management Discussion and Analysis](index=2&type=section&id=%E7%AE%A1%E7%90%86%E5%B1%A4%E8%A8%8E%E8%AB%96%E8%88%87%E5%88%86%E6%9E%90) During the reporting period, the company maintained strong business momentum with stable revenue growth, continuous innovation in cardiovascular interventional devices, particularly in biodegradable technology and structural heart disease treatment, and active expansion in domestic and international markets [Business Review](index=2&type=section&id=%E6%A5%AD%E5%8B%99%E5%9B%9E%E9%A1%A7) The company specializes in R&D, production, and commercialization of cardiovascular interventional devices, offering a broad product portfolio including congenital heart disease occluders, PFO and LAA occluders, heart valves, mechanical circulatory support, and access products, with many innovative products successfully commercialized or in clinical stages [Overall Operating Performance](index=5&type=section&id=%E6%95%B4%E9%AB%94%E7%B6%93%E7%87%9F%E6%A5%AD%E7%B8%BE) During the reporting period, the company achieved double-digit growth in revenue and net profit, significantly increased operating cash flow, and maintained steady growth in total assets Financial Highlights for the Six Months Ended June 30, 2025 | Indicator | June 30, 2025 (RMB million) | June 30, 2024 (RMB million) | Year-over-year growth rate (%) | | :--- | :--- | :--- | :--- | | Revenue | 329.7 | 249.1 | 32.4 | | Net Profit Attributable to Parent Company Shareholders | 182.0 | 140.2 | 29.8 | | Net Cash Generated from Operating Activities | 166.8 | 103.5 | 61.2 | | Total Assets (end of period) | 2,279.1 | 2,083.0 (beginning of reporting period) | 9.4 | | Net Assets (end of period) | 1,973.2 | 1,997.0 (beginning of reporting period) | -1.2 | [Congenital Heart Disease Occluder Products](index=2&type=section&id=%E5%85%88%E5%A4%A9%E6%80%A7%E5%BF%83%E8%87%9F%E7%97%85%E5%B0%81%E5%A0%B5%E5%99%A8%E7%94%A2%E5%93%81) The company maintains a leading position in congenital heart disease occluders, with third-generation oxide film and fourth-generation biodegradable occluder series successfully commercialized, becoming a cornerstone of business growth and embodying the "intervention without implant" philosophy - As of the date of this announcement, the Company has a total of **30** listed occluders, heart valve and accessory products, **4** products under registration review and preparation, and **28** pipeline products including occluders, heart valve and surgical accessories, and mechanical circulatory support at various R&D stages[6](index=6&type=chunk) - The fourth-generation MemoSorb® biodegradable atrial septal defect occluder product obtained the medical device registration certificate from the NMPA in August 2024 and has been rapidly commercialized[11](index=11&type=chunk) - Adhering to the technical concept of "intervention without implant," the Group will continue to promote the R&D and promotion of biodegradable materials[11](index=11&type=chunk) [PFO and LAA Occluder Products](index=6&type=section&id=%E5%8D%B5%E5%9C%93%E5%AD%94%E6%9C%AA%E9%96%89%E5%8F%8A%E5%B7%A6%E5%BF%83%E8%80%B3%E5%B0%81%E5%A0%B5%E5%99%A8%E7%94%A2%E5%93%81) First-generation cardiogenic stroke prevention products have been commercialized, with third-generation MemoSorb® biodegradable PFO occluders achieving over **RMB 200 million** in sales since launch, second-generation oxide film PFO occluders entering the registration application stage, and biodegradable LAA occluders entering multi-center clinical trials - The third-generation MemoSorb® biodegradable PFO occluder was approved for market in September 2023, with cumulative sales exceeding **RMB 200 million** as of June 30, 2025[12](index=12&type=chunk) - The second-generation oxide film PFO occluder has completed clinical follow-up and entered the registration application stage, with NMPA registration submission expected in **Q3 2025**[12](index=12&type=chunk) - The Bio-Lefort® biodegradable LAA occluder pipeline product has officially entered the multi-center clinical trial enrollment phase[12](index=12&type=chunk) [Aortic and Peripheral Occluder Devices](index=7&type=section&id=%E4%B8%BB%E5%8B%95%E8%84%88%E5%8F%8A%E5%A4%96%E5%91%A8%E5%B0%81%E5%A0%B5%E5%99%A8%E6%A2%B0) The company is strategically developing biodegradable aortic occluders and aortic embolization occluders in the aortic and peripheral fields, with both global innovative products having entered clinical trial stages, poised to address international challenges and offering promising market prospects - Both biodegradable aortic occluders and aortic embolization occluders have completed type testing and animal experiments, entering the clinical trial stage[13](index=13&type=chunk) - Currently, no targeted therapeutic devices for aortic dissection rupture and post-aortic aneurysm repair type II endoleak have been commercialized, making both of the Group's products global innovations[13](index=13&type=chunk) [Heart Valve Pipeline Products](index=7&type=section&id=%E5%BF%83%E8%87%9F%E7%93%A3%E8%86%9C%E5%9C%A8%E7%A0%94%E7%94%A2%E5%93%81) The ScienCrown® transcatheter aortic valve system was commercialized in early 2025, entering over **70** clinical centers in China, and the company is actively developing new products for aortic regurgitation, mitral valve repair, and replacement - The ScienCrown® transcatheter aortic valve system was officially commercialized in early 2025, having entered over **70** clinical centers in China for implantation[14](index=14&type=chunk) - A transcatheter aortic valve system for patients with isolated aortic regurgitation is currently under development, having completed animal experiments and type testing, with clinical trials planned for late 2025[14](index=14&type=chunk)[15](index=15&type=chunk) - The transapical mitral valve clip system is undergoing its second phase of clinical trials, with registration application to the NMPA expected to be postponed until 2026[15](index=15&type=chunk) [Mechanical Circulatory Support Products](index=8&type=section&id=%E6%A9%9F%E6%A2%B0%E5%BE%AA%E7%92%B0%E8%BC%94%E5%8A%A9%E7%94%A2%E5%93%81) The company has entered the mechanical circulatory support (MCS) device field, with a product line covering short-term and long-term ventricular assist systems, and multiple products in preclinical or type testing stages, aiming to become a core participant in this domain - The Company has entered the mechanical circulatory support (MCS) device field, with these devices designed to provide temporary or long-term support for patients requiring cardiac assistance[16](index=16&type=chunk) - The transcatheter left ventricular assist system for left ventricular support is in the preclinical type testing stage, with batch animal experiments already initiated[16](index=16&type=chunk) - The Company is one of the earliest pioneers in the domestic MCS field and is confident in becoming one of the most core and valuable participants in this area[16](index=16&type=chunk) [Access Products](index=8&type=section&id=%E9%80%9A%E8%B7%AF%E9%A1%9E%E7%94%A2%E5%93%81) The company boasts a rich pipeline of access products, with RF-Lance® radiofrequency puncture devices and needles approved for market, biodegradable LAA occluder delivery systems launched, and multiple valve surgery accessories (such as aortic valve balloon dilation catheters) approved or in clinical/registration stages - The RF-Lance® radiofrequency puncture device and RF-Lance® disposable radiofrequency atrial septal puncture needle were approved for market

格隆汇8月12日丨心泰医疗(02291.HK)宣布，本公司将于2025年8月22日（星期五）举行董事会会议，藉 以（其中包括）考虑及批准本公司及其附属公司截至2025年6月30日止六个月的未经审核中期业绩及其 发布，并考虑建议派发中期股息（如有）。 ...

（股份代號：2291） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 LEPU SCIENTECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.* 樂普心泰醫療科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 董事會會議通告 樂普心泰醫療科技（上海）股份有限公司（「本公司」）董事（「董事」）會（「董事會」） 謹此宣佈，本公司將於2025年8月22日（星期五）舉行董事會會議，藉以（其中包 括）考慮及批准本公司及其附屬公司截至2025年6月30日止六個月的未經審核中期 業績及其發佈，並考慮建議派發中期股息（如有）。 * 本公司註冊為香港法例第622章《公司條例》所定義的非香港公司，以其中文名稱及英文名 稱「LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.」註冊。 承董事會命 樂普心泰醫療科技（上海）股份有限公司 陳娟女士 董事長兼執行董事 中 ...

FF301 致：香港交易及結算所有限公司 公司名稱: 樂普心泰醫療科技（上海）股份有限公司 (「本公司」) 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02291 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 346,749,997 | RMB | | 1 RMB | | 346,749,997 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 346,749,997 | RMB | | 1 RMB | | 346,749,997 | 本月底法定/註冊股本總額： RMB 346,749,997 備註： 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2 ...

消息上，为支持药品和医疗器械创新发展，国家医保局日前制定新上市药品首发价格机制，新增了100 多项与医疗新技术相关的价格项目，促进高端医疗设备的临床转化应用。 中信建投研报称，港股医疗器械公司整体创新性较强，多家企业即将步入扭亏为盈或业绩快速释放的阶 段。今年以来，有创新产品上市、技术突破实现license-out可能的催化，以及账上现金丰富、业绩快速 释放、估值低位的部分18A器械公司，年初至今有翻倍以上的涨幅；部分业绩高增长的低估值龙头器械 公司年初至今亦有较好表现。(格隆汇) 心泰医疗(2291.HK)盘中一度涨近8%，高见27.4港元创4月底以来新高，近一个月累计升幅达30%，总市 值93亿港元。 公司是稳健盈利的港股创新医疗器械企业。根据弗若斯特沙利文统计，就2021年的销售收入而言，心泰 医疗是中国最大的先天性心脏病封堵器制造商（市场份额为38%）。 ...